T-cell checkpoint antibodies have revolutionized immunotherapy for cancer, including renal cancer. At Providence Cancer Institute, several clinical trials of these novel approaches are now open to patients with renal cell carcinoma (RCC), including a new phase III study evaluating the effectiveness of checkpoint immunotherapy in combination with an investigational cytokine agent, compared to standard-of-care targeted therapy.
A new phase 3 study open at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, will evaluate the curative potential of adjuvant pembrolizumab in patients with high-risk or locally-advanced cutaneous squamous cell carcinoma (LA cSCC).
In a matter of minutes William Kennedy went from explaining how unfortunate he is – with his diagnosis of incurable cancer – to how fortunate he is – finding Providence and hope. He told the attendees at the 2019 Providence Creating Hope Dinner that time is now truly a gift – and they can give him, and others fighting cancer, more time by giving generously to research.
In the last year, the combination of pembrolizumab (Keytruda) with chemotherapy has become a frontline treatment for people with metastatic non-small cell lung cancer (NSCLC). The FDA granted full approval for the combination treatment last August based on studies that showed a clear survival benefit over chemotherapy alone.
A newly opened study for metastatic HER2-negative breast cancer will evaluate an alternative systemic treatment combination that omits or delays the use of chemotherapy while improving the efficacy and durability of response.
Identical twin astronauts – one grounded on Earth and the other launched into space – proved to be fascinating research subjects for Providence genomics expert and cancer researcher Brian Piening, Ph.D., who helped NASA explore the effects of long-term space missions on the body. Dr. Piening now uses what he learned to personalize treatment for cancer patients at Providence.
Providence Cancer Institute’s commitment to advancing immunotherapy research and clinical trials is, again, making a difference in the lives of cancer patients at home and around the world.
The light-activated drug ASP-1929 is showing promise as a potential new treatment for people with recurrent head and neck cancers. A new study of this first-in-class, precision targeted therapy is opening soon at Providence Cancer Institute.
Phase 1 studies are the springboard for advancing new cancer treatments. Through phase 1 studies, the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is often able to offer patients first-in-human clinical trials of immunotherapies and other novel cancer therapies, including these two recently opened studies.
Emerging research is finding that immunotherapy may extend survival for some women with triple-negative breast cancer. Providence Cancer Institute, a leader in immunotherapy research, is actively investigating options for this aggressive cancer.